Aspirin resistance in ischaemic heart disease;Oporność na kwas acetylosalicylowy: W chorobie niedokrwiennej serca

Kardiologia Polska

Volumn 62, Issue 1, 2005, Pages 14-25

  Kuliczkowski, Wiktor ^a,b   Halawa, Bogumił ^a,b   Korolko, Bozena ^a,b   Mazurek, Walentyna ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b Wroclaw Medical University Katedra i Klinika Kardiologii   (Poland)

Author keywords

Aspirin resistance; CABG; Ischaemic heart disease

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; DISEASE ASSOCIATION; DISEASE COURSE; EXERCISE TEST; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; STABLE ANGINA PECTORIS; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM;

EID: 13444252968     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Schrör K.: Aspirin and platelets. Semin. Thromb. Haemost. 1997, 23, 349-56.
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. B.M.J. 2002, 324, 71-86.
3. Nair G.V., Davis C.J., McKenzie M.E. et al.: Aspirin in patients with coronary artery disease: is it simply irresistible? J. Thromb. Thrombolysis. 2001, 11, 117-26.
4. Eikelboom J.W., Hirsh J., Weitz J.I. et al.: Aspirin-resistant thromboxane biosynthesis and risk of myocardial infarction, stroke or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002, 105, 1650-5.
5. Patrono C.: Aspirin resistance: definition, mechanisms and clinical read-outs. J. Thromb. Haemost. 2003, 1, 1710-3.
6. McKee S.A., Sane D. C., Dellargyris E.N.: Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms and clinical significance. Thromb. Haemost. 2002, 88, 711-5.
7. Hurlen M., Seljeflot I., Arnesen H.: The effect of different antithrombotic regiments on platelet aggregation after myocardial infarction. Scand. Cardiovasc. J. 1988, 32, 233-7.
8. Grotemeyer K.H.: Effects of acetylsalicylic acid in stroke patients: evidence of nonresponders in a subpopulation of treated patients. Thromb. Res. 1991, 63, 587-93.
9. Grotemeyer K.H.: Two-year follow-up of aspirin responder and aspirin non-responder. A pilot-study including 180 post-stroke patients. Thromb. Res. 1993, 71, 397-403.
10. Helgason C.M., Tortorice K.L., Winkler S.R. et al.: Aspirin response and failure in cerebral infarction. Stroke 1993, 24, 345-50.
11. Helgason C.M., Bolin K.M., Hoff J.A. et al.: Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994, 25, 2331-6.
12. Buchanan M.R., Brister S.J.: Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can. J. Cardiol. 1995, 11, 221-7.
13. Mueller M.R., Salat A., Stangl P. et al.: Variable platelet response to low-dose ASA and risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb. Haemost. 1997, 78, 1003-7.
14. Gum P.A., Konke-Marchant K., Poggio E.D. et al.: Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am. J. Cardiol. 2001, 88, 230-5.
15. Gum P.A., Kottke-Marchant K., Welsh P.A. et al.: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J. Am. Coll. Cardiol. 2003, 41, 961-5.
16. Nicholson N.S., Panzer-Knodle S.G., Haas N.F. et al.: Assessment of platelet function assays. Am. Heart J. 1998, 135, S170-8.
17. Zimmermann N., Kienzle P., Weber A.A. et al.: Aspirin resistance after coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg. 2001, 121, 982-4.
18. Helgason C.M., Bolin K.M., Hoff J.A. et al.: Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994, 25, 2331-6.
19. Anderson K., Hurlen M., Arnesen H. et al.: Aspirin non-responsiveness as measured by PFA-1000 in patients with coronary artery disease. Thromb. Res. 2002, 108, 37-42.
20. Halushka M.K., Halushka P.V.: Why are some individuals resistant to the cardioprotective effects of aspirin? Circulation 2002, 105, 1620-2.
21. Michelson A.D., Furman M.I., Goldschmidt-Clermont P. et al.: Platelet GP IIIa P1 (A) polymorphisms display different sensitivities to agonists. Circulation 2000, 101, 1013-8.
22. Zimmermann N., Wenk A., Kim U. et al.: Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003, 108, 542-7.
23. Boulos C., Jiang H., Balazy M.: Diffusion of peroxynitrite into the human platelet inhibits cyclooxygenase via nitration of tyrosine residues. J. Pharmacol. Exp. Ther. 2000, 293, 222-9.
24. Ross R.: Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 1999, 340, 115-26.
25. Ikonomidis I., Andreotti F., Economou E. et al.: Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999, 100, 793-8.
26. Ersoz G., Tikiz H., Yakaryilmaz A. et al.: Differential effect of aspirin on platelet aggregation in patients with coronary artery disease in relation with associated risk factors. Jpn. Heart J. 2003, 44, 21-9.
27. Bhatt D.L., Chew D.P., Hirsch A. T. et al.: Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001, 103, 363-8.
28. Schreiber T.L., Macina G., Bunnell P. et al.: Unstable angina or non-Q-wave infarction despite long term aspirin: response to thrombolytic therapy with implications on mechanism. Am. Heart J. 1990, 120, 248-55.
29. Alexander J.H., Harrington R.A., Tuttle R.H. et al.: Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. Am. J. Cardiol. 1999, 83, 1147-51.